Introduction KRAS G12C mutations represent a clinically important molecular subtype of metastatic colorectal cancer (mCRC), occurring in approximately 3–4% of cases and often associated with aggressive disease biology and limited responsiveness to conventional therapies. Recent advances in KRAS G12C inhibitors combined with EGFR blockade have demonstrated promising activity in refractory disease, opening new possibilities for biomarker-driven treatment strategies in colorectal cancer.
Introduction
KRAS G12C mutations represent a clinically important molecular subtype of metastatic colorectal cancer (mCRC), occurring in approximately 3–4% of cases and often associated with aggressive disease biology and limited responsiveness to conventional therapies. Recent advances in KRAS G12C inhibitors combined with EGFR blockade have demonstrated promising activity in refractory disease, opening new possibilities for biomarker-driven treatment strategies in colorectal cancer.
Problem Statement
Frail and elderly patients with unresectable mCRC frequently cannot tolerate standard doublet or triplet chemotherapy regimens because of age, comorbidities or impaired performance status. Current low-intensity fluoropyrimidine-based approaches offer only modest efficacy, and many vulnerable patients never reach later-line targeted therapies. Whether KRAS G12C-targeted combinations can be safely and effectively integrated earlier in treatment using chemotherapy-sparing strategies remains unknown.
Summary
The COLOSOTO trial is the first prospective study evaluating first-line treatment with 5-fluorouracil, panitumumab and sotorasib in frail or elderly patients with unresectable KRAS G12C-mutated metastatic colorectal cancer who are unfit for intensive chemotherapy. Building on encouraging activity observed with KRAS G12C inhibition plus EGFR blockade in refractory settings, this study investigates whether earlier deployment of this biologically driven combination can improve outcomes while maintaining tolerability in a clinically vulnerable population. The trial specifically targets patients traditionally underserved by standard treatment paradigms, including older adults and patients with impaired performance status. By combining limited-intensity chemotherapy with dual molecular targeting, the strategy aims to balance efficacy and toxicity while potentially avoiding the complications associated with aggressive cytotoxic regimens. The study also incorporates comprehensive geriatric assessment, quality-of-life evaluation and translational biomarker analyses including circulating tumor DNA monitoring, emphasizing a modern personalized oncology approach. Although limited by its single-arm design and relatively small sample size, the trial addresses a major unmet need in gastrointestinal oncology and may establish a new first-line therapeutic paradigm for frail patients with KRAS G12C-mutated colorectal cancer.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.